Myriad Genetics, Inc. (NASDAQ:MYGN) is making waves at the 2025 ASCO Annual Meeting, presenting seven new research studies ...

Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that data from more ...

The new cancer research, published in The Lancet Oncology journal, examined the levels of circulating tumor DNA (ctDNA) found in cancer patients' blood. Approximately 80% of stage 3 melanoma ...

Patients with detectable ctDNA before treatment had a shorter duration of clinical benefit and shorter overall survival. Having detectable circulating tumor DNA (ctDNA) before treatment is ...

Evidence for plasma-based circulating tumor DNA (ctDNA) as a prognostic and predictive marker in urothelial carcinoma is helping to transform the diagnostic and management landscape. Joaquin ...

DNA in sarcoma shows 89% sensitivity, while Indian data shows declining protein intake, highlighting personalized care and ...

ctDNA monitoring post-surgery can identify high recurrence risk in skin cancer, aiding treatment decisions. Droplet digital PCR (ddPCR) effectively detects minimal residual disease (MRD ...

Researchers tested the performance of the whole-genome sequencing-based assay head-to-head against ctDNA and ddPCR assays.

"We think [patients with resected stage III melanoma] would most likely benefit from ctDNA measurements shortly after their surgery -- [for example} within 12 weeks or less as was done in this ...

This extraordinary breadth of data includes analyses of thousands of patients, demonstrating Natera’s leadership in circulating tumor DNA (ctDNA) monitoring and molecular residual disease (MRD) ...